About Roxadustat

Roxadustat is the first new oral drug for renal anemia approved in China. It was approved by the National Drug Administration (NMPA) in December 2018 for the treatment of anemia in dialysis patients with chronic kidney disease. The drug had not been marketed in any other country before it was approved for sale in China. As the world's first hypoxia inducible factor, prolyl hydroxylase inhibitor (HIF-PHI), Rosastatin can effectively promote erythropoietin by promoting endogenous erythropoietin production, improving iron absorption and utilization, reducing iron regulation, and avoiding the negative effects of inflammation on hemoglobin and erythropoiesis. Rosaspartate has been shown to induce erythropoiesis. In many subgroups of patients with chronic kidney disease, rosamus can maintain erythropoietin levels in or near normal physiological range, thereby increasing the number of red blood cells, while not affected by inflammation, but also avoid intravenous iron supplementation. It is reported that the price of 50mg*3s is 498 yuan, that is, 166 yuan per 50mg drug.